Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03416153 · ClinicalTrials.gov registry record · Phase 2
Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer
A Phase 2 study of Oropharynx Cancer, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 91
- Enrollment target
- 2
- Study locations
NCT03416153 is a Phase 2 study of Oropharynx Cancer that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 91 participants, below the 129-participant average among 26 other Oropharynx Cancer trials with a reported enrollment target (29% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03416153, a Phase 2 study of Oropharynx Cancer, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 91 participants
- Enrollment target
- 2
- Study locations
Study Summary
This prospective study aims to utilize pre- and mid-treatment PET-CT to guide de-escalation of radiation therapy in HPV-related squamous cell carcinoma of the oropharynx.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- RADIATION Radiation Therapy
Study Locations (2)
Michigan
- University of Michigan Hospital - Ann Arbor
- VA Ann Arbor Healthcare System - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2018-05-21 |
| Est. Completion | 2025-05-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03416153
The ClinicalTrials.gov registry entry for NCT03416153 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 129-participant average among 26 other Oropharynx Cancer trials with a reported enrollment target (29% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Oropharynx Cancer appearing as the primary indexed condition, and to 3 interventions - of which Carboplatin is the first listed.
NCT03416153 reports 2 study locations spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT03416153 about?
NCT03416153 is a clinical study titled "Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer". This prospective study aims to utilize pre- and mid-treatment PET-CT to guide de-escalation of radiation therapy in HPV-related squamous cell carcinoma of the oropharynx.
What is the current status of trial NCT03416153?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 91 participants. The study started on 2018-05-21. Estimated completion is 2025-05-05.
What conditions does trial NCT03416153 study?
This clinical trial studies the following conditions: Oropharynx Cancer.
What interventions are being tested in trial NCT03416153?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT03416153?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03416153 being conducted?
This trial has 2 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharynx Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
RECRUITING · Phase 2
-
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
RECRUITING · Phase 2
-
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
RECRUITING · Phase 2
-
Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer)
RECRUITING · Phase 2
-
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
RECRUITING · Phase 2
-
Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.